4D Molecular Therapeutics, Inc. (FDMT) 4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
4D Molecular Therapeutics, Inc. NASDAQ:FDMT Healthcare · Biotechnology
Mkt Cap $657.41M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
4DMT Announces New Employment Inducement Grants
4DMT granted 13 new non-executive employees inducement awards covering options on 260,000 shares and 157,600 RSUs under its 2025 Employment Inducement Award Plan.
Options carry a $12.36 exercise price, matching the October 13, 2026 closing price on the grant date, and the grants were made under Nasdaq Rule 5635(c)(4).
This is routine hiring-related equity disclosure with no bearing on the company's clinical programs or financial position.
• 16d ago AI analysis › Press Release
4DMT to Host Investor Day on October 21, 2026
4D Molecular Therapeutics will host an Investor Day on October 21, 2026, in New York City starting at 10:30am ET, with a webcast available.
The event will cover the advancing clinical profile and commercial vision for lead candidate 4D-150, with a KOL panel including Drs. Khanani, Awh, Eichenbaum, and Haug.
4D-150 is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema; 4D-710 targets cystic fibrosis. This is a scheduling notice, not a data disclosure.
• 27d ago AI analysis › Press Release ● Major ⚠ 2
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
4D Molecular Therapeutics enrolled the first patients in 4SIGHT, a global Phase 3 trial (N=514) of 4D-150 in treatment-naïve diabetic macular edema, the company's second Phase 3 program after the 4FRONT wet AMD trials.
Updated 2-year SPECTRA Part 1 data showed 4D-150 was well tolerated with no intraocular inflammation, and at the Phase 3 dose patients gained a mean of +10.8 BCVA letters with a 176 µm CST reduction and 61% treatment burden reduction versus on-label aflibercept Q8W.
The company has FDA RMAT designation for 4D-150 in DME and alignment with FDA and EMA on a potential BLA filing based on the single 4SIGHT trial plus SPECTRA, PRISM and 4FRONT data.
• 1mo ago AI analysis › Press Release ● Major
4DMT Announces New Employment Inducement Grants
globenewswire.com • 1mo ago Press Release
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics announced that management will present and participate in one-on-one meetings at the Wells Fargo 2026 Healthcare Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026.
Archived webcasts of these presentations will be available on the Investors section of the 4DMT website for up to one year.
The company's lead product candidate, 4D-150, is currently in Phase 3 development for wet age-related macular degeneration, while 4D-710 targets cystic fibrosis.
• 2mo ago AI analysis › Press Release
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 35,200 Restricted Stock Units to five new non-executive employees on August 11, 2026.
The inducement awards were made pursuant to the Company’s 2025 Employment Inducement Award Plan and Nasdaq Rule 5635(c)(4).
The company continues to advance its pipeline, including lead candidate 4D-150 for wet age-related macular degeneration, currently in Phase 3 development.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4DMT completed enrollment for the 4FRONT-2 Phase 3 trial of 4D-150 in wet AMD, with topline data expected in H2 2027, and reported positive 2-year data from the PRISM Phase 2b trial showing an up to 87% reduction in treatment burden.
The company secured a $200 million strategic credit facility with Hercules Capital, drawing an initial $20 million, bringing the total cash position to $430.6 million to fund operations into the second half of 2028.
Q2 financial results showed a net loss of $72.9 million, driven by increased R&D expenses of $68.3 million to support the Phase 3 programs, while collaboration revenue reached $3.8 million.
• 2mo ago AI analysis › Press Release ● Major
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
4DMT announced positive 2-year data from the PRISM Phase 2b trial of 4D-150 in wet age-related macular degeneration, demonstrating maintained visual acuity and durable treatment burden reduction.
The overall cohort achieved a 78% reduction in supplemental injections compared to standard care projections, with recently diagnosed patients seeing an 87% reduction, and no new intraocular inflammation cases were observed after the initial six months.
These results reinforce management's confidence in the ongoing 4FRONT Phase 3 program, positioning 4D-150 as a potential foundational backbone therapy for retina specialists.
• 3mo ago AI analysis › Press Release
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 37,900 Restricted Stock Units to six new non-executive employees on July 14, 2026.
The grants were issued under the Company’s 2025 Employment Inducement Award Plan in accordance with Nasdaq Rule 5635(c)(4) as an inducement for employment.
This announcement is a standard corporate governance filing regarding hiring incentives and does not alter the company's clinical or financial outlook.
• 3mo ago AI analysis › Press Release
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists, focusing on 2-year follow-up data from the PRISM Phase 2b trial of 4D-150 in neovascular AMD.
The presentation is scheduled for July 18, 2026, and materials will be made available on the company's website following the event.
4D-150 is the company's lead product candidate, a gene therapy designed to provide multi-year sustained delivery of anti-VEGF biologics, currently in Phase 3 development for wet age-related macular degeneration.
• 4mo ago AI analysis › Press Release ● Major
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
4D Molecular Therapeutics completed enrollment for the 4FRONT-2 global Phase 3 trial of 4D-150 in wet AMD approximately four months ahead of schedule and with over-enrollment anticipated at more than 500 patients.
The 4FRONT-2 trial is a randomized, double-masked study comparing 4D-150 to aflibercept, with 52-week topline data expected in the second half of 2027. The company also noted that 4FRONT-1 topline data is anticipated in the first half of 2027.
Management attributed the high enrollment rate to strong enthusiasm from investigators and patients for a durable backbone therapy aimed at reducing the burden of frequent anti-VEGF injections.
• 4mo ago AI analysis › Press Release ● Major
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
4D Molecular Therapeutics entered into a strategic credit facility with Hercules Capital for up to $200 million, featuring an initial $20 million draw and additional tranches available through mid-2027 and upon milestone achievements.
The company's current cash position of $458 million, combined with this non-dilutive capital, is expected to fund operations into the second half of 2028, providing flexibility for Phase 3 development.
Proceeds will support the advancement of lead product candidate 4D-150 for wet age-related macular degeneration and diabetic macular edema.
• 4mo ago AI analysis › Press Release
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
Former 4D Molecular Therapeutics (FDMT) CFO August Moretti has joined the board of directors of Vivani Medical, Inc.
Moretti served as CFO of FDMT from 2019 until his retirement in September 2023.
At Vivani, he will serve as chair of the Audit Committee and member of the Compensation Committee.
• 4mo ago AI analysis › Press Release
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 66,900 Restricted Stock Units to seven new non-executive employees.
The grants were issued under the Company’s 2025 Employment Inducement Award Plan to comply with Nasdaq Rule 5635(c)(4) for new hires.
This is a routine operational disclosure with minimal dilutive impact on the shareholder base.
• 4mo ago AI analysis › Press Release
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 3:10 p.m. ET.
The company will also participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 2:00 p.m. ET.
Archived webcasts of these presentations will be available on the company’s investor relations website for up to one year.
• 5mo ago AI analysis › Press Release
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 141,100 Restricted Stock Units to 14 new non-executive employees.
The grants were issued under the Company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
This is a routine compensation disclosure with negligible impact on shareholder equity or near-term dilution.
• 5mo ago AI analysis › Press Release ● Major
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
globenewswire.com • 5mo ago Press Release
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics announced that management will present and participate in one-on-one meetings at upcoming investor conferences in May.
The scheduled presentations include the BofA Securities 2026 Healthcare Conference on May 13 and the RBC 2026 Global Healthcare Conference on May 19.
Archived copies of the webcasts will be available on the Investors section of the 4DMT website for up to one year.
• 5mo ago AI analysis › Press Release ● Major
4DMT Announces New Employment Inducement Grants
globenewswire.com • 6mo ago Press Release ● Major
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
globenewswire.com • 7mo ago Press Release
4DMT to Participate in Upcoming Investor Meetings
globenewswire.com • 7mo ago 
